Sophia Genetics
EPFL Innovation Park
Batiment D
Lausanne
CH-1015
Tel: 41-21-693-90-44
Website: http://www.sophiagenetics.com/
Email: info@sophiagenetics.com
86 articles about Sophia Genetics
-
Laboratorio Curie Expands Relationship with SOPHiA GENETICS
9/13/2023
SOPHiA GENETICS has expanded its relationship with Laboratorio Curie.
-
SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform
9/7/2023
SOPHiA GENETICS is helping excel the use of precision medicine to treat advanced ovarian cancer.
-
CHU Bordeaux is live on SOPHiA GENETICS
8/30/2023
SOPHiA GENETICS announced that CHU Bordeaux, a full-service hospital servicing the population of Bordeaux and the surrounding area, has completed implementation of the SOPHiA DDM™ Platform into its organization.
-
SOPHiA GENETICS Expands Relationship with Gustave Roussy
8/22/2023
SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe.
-
Tulane University School of Medicine Uses SOPHiA GENETICS to Advance Research of Blood Cancers
8/8/2023
SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, announced that the Tulane University School of Medicine in New Orleans, Louisiana is live on SOPHiA GENETICS technology.
-
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023
8/8/2023
SOPHiA GENETICS SA today reported financial results for the second quarter ended June 30, 2023.
-
SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2023 on August 8, 2023
7/25/2023
SOPHiA GENETICS SA today announced it will release its financial results for the second quarter of fiscal 2023 before U.S. markets open on Tuesday, August 8, 2023.
-
Ankara Etlik City Hospital is Live on SOPHiA GENETICS Platform
6/22/2023
SOPHiA GENETICS announced that Ankara Etlik City Hospital, the largest hospital in the capital city of Turkey, is live on the SOPHiA DDM™ Platform.
-
Institute of Oncology Ljubljana Leverages SOPHiA DDM™ Platform for Cancer Research
5/24/2023
SOPHiA GENETICS announced that the Institute of Oncology Ljubljana, a comprehensive public institution for detection, treatment and research of cancer, based in Ljubljana, Slovenia, is live on SOPHiA DDM™.
-
Dasa Expands Its Capabilities with SOPHiA GENETICS
5/15/2023
SOPHiA GENETICS, a cloud-native software company and the leader in data-driven medicine, celebrates with longstanding partner, Dasa, the largest integrated healthcare network in Brazil, as it reaches a milestone of 2,000 samples analyzed for HRD status.
-
SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2023
5/9/2023
SOPHiA GENETICS SA reported financial results for the first quarter ended March 31, 2023.
-
SOPHiA GENETICS’ SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty Laboratory Limited
5/3/2023
SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Unipath Specialty Laboratory Limited, one of the leading diagnostic brands in India, is live on the SOPHiA DDM™ Homologous Recombination Deficiency Solution.
-
SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023
4/25/2023
SOPHiA GENETICS today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023.
-
Tel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS
4/4/2023
SOPHiA DDMTM HRD Solution will help empower clinical researchers to advance cancer research SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Tel Aviv Sourasky Medical Center, the largest acute care facility in Israel, has chosen to use SOPHiA DDM™ to enhance its genetic testing capabilities.
-
Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test
3/28/2023
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay.
-
SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis
3/14/2023
SOPHiA GENETICS is partnering with Agilent to offer a comprehensive solution for cancer analysis.
-
SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing
3/1/2023
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS).
-
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
3/1/2023
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.
-
Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
2/28/2023
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced that Synergy Oncology, part of Synergy Laboratories, a full-service diagnostic laboratory based in Mobile, Alabama, will use SOPHiA DDM™ to develop a new cancer profiling solution.
-
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 on March 7, 2023
2/23/2023
SOPHiA GENETICS today announced it will release its financial results for the fourth quarter and full year of fiscal 2022 before U.S. markets open on Tuesday, March 7, 2023.